Trial Profile

A clinical study assessing LY03010 (Paliperidone Palmitate Injectable Suspension) Schizophrenia and bipolar disorder

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paliperidone (Primary)
Indications Bipolar disorders; Schizophrenia
Focus Therapeutic Use
Sponsors Luye Pharma Group

Most Recent Events

23 Feb 2023 According to a Luye Pharma Group media release, company will submit the New Drug Application (NDA) for this drug to the U.S. Food and Drug Administration (FDA) through the 505(b)(2) pathway.
23 Feb 2023 According to a Luye Pharma Group media release, today announced that it has received approval by the competent authorities to initiate the first clinical trial in Europe.
15 Sep 2021 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com